Pediatric Center, Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Pediatric Hematology, Qingdao Children's Hospital, Qingdao, China.
Orphanet J Rare Dis. 2018 Apr 6;13(1):48. doi: 10.1186/s13023-018-0782-x.
The study aim was to verify the feasibility of a diagnostic algorithm with the evaluation of beta glucocerebrosidase (GBA) activity on dried blood spots (DBS) in screening high-risk Gaucher disease (GD) children in China, and to investigate the GD prevalence in this selected population.
Children were recruited from 20 departments of pediatrics or children's hospitals in Shandong Province, China, due to splenomegaly and/or thrombocytopenia associated with one or more of the following creteria: anemia, history of bone pain, monoclonal gammopathy of unknown significance (MGUS), polyclonal gammopathy and splenectomy. GBA activity on DBS was tested, and patients with DBS GBA activity under 30 nmol/h.ml were recalled to assess enzyme assay with gold standard and molecular GBA gene analysis on leukocytes.
A total of 73 children (47 boys and 26 girls) were enrolled in this study. GBA activity DBS < 30 nmol/h.ml was found in 18 (23.7%) children among which four (three boys and one girl) were diagnosed as GD with a median age 1.5 years, and the prevalence in this pediatric population was 5.5% (1.5%~ 13.4%). Three new mutations of GBA found in the four GD patients, L264I, A100Cfs*7 and D399E, have not been reported before.
With evaluation of GBA activity on DBS as a preliminary screening method, the diagnostic algorithm used in this study is appropriate to make early diagnosis for GD patients with mild symptoms or atypical symptoms and avoid diagnosis delay.
Not applicable.
本研究旨在验证通过检测干血斑(DBS)β-葡萄糖脑苷脂酶(GBA)活性评估诊断算法在中国高风险戈谢病(GD)儿童筛查中的可行性,并调查该选定人群中 GD 的患病率。
从山东省 20 个儿科或儿童医院的 20 个科室招募因脾肿大和/或血小板减少症且伴有以下一种或多种标准的儿童:贫血、骨痛史、不明意义的单克隆丙种球蛋白血症(MGUS)、多克隆丙种球蛋白血症和脾切除术。检测 DBS 中的 GBA 活性,对 DBS GBA 活性<30nmol/h.ml 的患者进行召回,用金标准评估酶活性检测,并对白细胞进行分子 GBA 基因分析。
本研究共纳入 73 名儿童(47 名男孩和 26 名女孩)。在 18 名(23.7%)儿童中发现 DBS GBA 活性<30nmol/h.ml,其中 4 名(3 名男孩和 1 名女孩)被诊断为 GD,中位年龄为 1.5 岁,该儿科人群的患病率为 5.5%(1.5%~13.4%)。在 4 名 GD 患者中发现了 3 种新的 GBA 突变,L264I、A100Cfs*7 和 D399E,以前尚未报道过。
使用 DBS 上 GBA 活性评估作为初步筛查方法,本研究中使用的诊断算法适用于对症状轻微或不典型的 GD 患者进行早期诊断,避免诊断延迟。
不适用。